Generated by AI
Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification. Its work centers on extrachromosomal DNA (ecDNA), a biological mechanism that can fuel cancer growth, adaptation, and resistance to existing treatments. Using its proprietary Spyglass platform, Boundless Bio identifies ecDNA-related targets and designs ecDNA-directed therapeutic candidates intended to disrupt the pathways cancer cells use to survive. The company’s current pipeline includes oral small-molecule programs such as BBI-940 and other ecDNA-directed therapies being evaluated in clinical studies across hard-to-treat cancer types. Boundless Bio Inc. operates in the biotechnology sector and serves the broader oncology market with a research-driven approach aimed at addressing unmet needs in patients with oncogene-amplified cancers.
Website10955 Alexandria Way
San Diego, CA, 92121
United States
The latest articles about BOLD.
Beam Therapeutics (BEAM) sues YolTech and its U.S. partner Serapha for alleged trade secret theft related to a gene editing medicine. Read more here.
Summary of Jun 23's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Summary of Dec 3's posts. Generated by AI.
No summary yet.
No summary yet.
Investors talking about BOLD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.